iZafe Group AB (FRA:M02) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:M02 iZafe Group AB FRA:M02
48 GF Score
Price €0.03
GF Value €0.04
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is iZafe Group AB Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

FRA:M02
48GF Score
iZafe Group AB FRA:M02
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is iZafe Group AB (FRA:M02) Overvalued in 2026?

Based on GuruFocus' analysis, iZafe Group AB stock appears to be undervalued. The current stock price of €0.03 is trading 30% below its estimated GF Value™ of €0.04. GuruFocus considers iZafe Group AB to be Possible Value Trap.

Key valuation signals for FRA:M02:

  • Total Noninterest Expense:
  • GF Value™: €0.04 vs. price of €0.03 (30% below fair value)
  • GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the FRA:M02 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


iZafe Group AB Business Description

Other Exchanges IZAFE B:Sweden
Address David Bagares Gata 3, Stockholm, SWE, 111 38
iZafe Group AB is a Developer of a digital medication dispensing system designed to enhance patient safety and reduce medication errors in home healthcare. The company offers a smart medication robot with automated dispensing and remote monitoring, enabling public and private healthcare providers in Sweden, the Nordics, and international markets, improved treatment adherence and reduced caregiver workload.
48GF Score

Get the complete analysis for FRA:M02

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price
€0.04
GF Value